2014
DOI: 10.1590/s1677-5538.ibju.2014.03.09
|View full text |Cite
|
Sign up to set email alerts
|

Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes

Abstract: ARTICLE INFO ______________________________________________________________ ______________________Purpose: To evaluate the association between prostatic inflammation and lower urinary tract symptoms (LUTS), and to identify the effects of prostatic inflammation on the treatment with an alpha blocker. Materials and Methods:111 Participants who were aged ≥ 50 years, the presence of LUTS (maximal flow rate < 20 m/s, IPSS ≥ 11), and an elevated PSA level (3-20ng/mL) were treated with tamsulosin 0.2mg once daily for… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…However, this study did not distinguish between the effect of α 1 -adrenoceptor antagonists and 5ARIs. Another retrospective Korean study in 111 LUTS/BPH patients treated with the α 1 -adrenoceptor antagonist tamsulosin 0.2 mg/day for only 3 months indicated that the improvement in LUTS was independent of the inflammation grade [ 39 ]. However, multivariate analysis suggested that longer duration of treatment was associated with decreased symptomatic improvement (odds ratio 0.92; 95% CI 0.85–0.99).…”
Section: Methodsmentioning
confidence: 99%
“…However, this study did not distinguish between the effect of α 1 -adrenoceptor antagonists and 5ARIs. Another retrospective Korean study in 111 LUTS/BPH patients treated with the α 1 -adrenoceptor antagonist tamsulosin 0.2 mg/day for only 3 months indicated that the improvement in LUTS was independent of the inflammation grade [ 39 ]. However, multivariate analysis suggested that longer duration of treatment was associated with decreased symptomatic improvement (odds ratio 0.92; 95% CI 0.85–0.99).…”
Section: Methodsmentioning
confidence: 99%
“…The mean change from baseline was 2.1 ± 7.9 ( P = 0.0767) in patients taking only BDP and 4.7 ± 7.9 ( P <.0001) in patients also taking SR. This may indicate a worsening of IPSS, especially in patients taking both treatments, although a temporary increase in score prior to final improvement is quite common in inflammations of the lower urinary tract [ 23 ]. In fact, IPSS is more accurate for the evaluation of voiding symptoms, whereas BDP is an anti-inflammatory medication and is therefore meant to act mainly on symptoms of the lower urinary tract defined as storage symptoms [ 24 ].…”
Section: Discussionmentioning
confidence: 99%
“…Quando analisado a relação entre os pacientes com STUI moderado a grave (I-PSS>8) e o nível de PSA, foi obtido média de PSA de 2,90 ng/mL (p=0,063), sugerindo uma tendência de relação entre níveis mais elevados de PSA e a progressão de aumento do volume da próstata. Outro estudo que analisou a relação entre o nível basal do PSA e a progressão do crescimento do volume prostático, observou-se que 61,3% dos casos da amostra também apresentaram um PSA > 2,5 ng/mL (PATEL et al, 2018) Estudos enfatizam que o volume prostático acima de 40g e o nível do PSA acima de 1,6 ng/mL são parâmetros de risco para agravamento de STUI, e há uma relação direta entre o envelhecimento e a progressão de aumento do volume da próstata, com aumento médio de 0,6 ml por ano (CHUGHTAI et al, 2016;LEE et al, 2014;ROEHRBORN, 2008). Neste sentido, o presente estudo demonstrou resultados semelhantes obtendo o valor médio de volume prostático de 46,7g, e ao analisar a relação entre o volume da próstata com os graus leve (I-PSS<8), moderado (I-PSS 8 -19) e grave (I-PSS 20 -35) de progressão de sintomas prostáticos, obteve-se as médias de volume: 38,71g; 46,72g; e 53g, respectivamente.…”
Section: Variávelunclassified